Open AccessShort-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma
Author(s) -
Alexander Y. Kim,
Shelby Frantz,
Pranay Krishnan,
Danielle DeMulder,
T. Caridi,
G. Lynskey,
James B. Spies
Publication year - 2017
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0183861
Subject(s) - medicine , hepatocellular carcinoma , common terminology criteria for adverse events , adverse effect , single center , response evaluation criteria in solid tumors , liver function , transcatheter arterial chemoembolization , retrospective cohort study , drug , radiology , gastroenterology , oncology , progressive disease , chemotherapy , pharmacology
Purpose To review the initial imaging responses after drug-eluting embolic trans-arterial chemoembolization (DEE-TACE) delivered with the Surefire Infusion System ® for the treatment of hepatocellular carcinoma (HCC). Methods Single center retrospective evaluation of patients who underwent DEE-TACE for HCC, delivered with SIS. Information was gathered from available medical records. Treatment response rates were assessed using the modified Response Evaluation Criteria in Solid Tumors criteria. Assessment of adverse events was categorized per Common Terminology Criteria for Adverse Events version 4.03. Results Twenty-two patients with 39 hepatocellular carcinoma lesions were treated with the surefire infusion system. Complete response was demonstrated in 32% of patients and 54% of lesions after a single treatment session. Overall disease response was demonstrated in 91% of patients and 85% of lesions after a single treatment. No grade 3 or higher elevations in liver function tests were demonstrated in the short-term. Conclusion SIS delivered DEE-TACE leads to a higher than expected initial response in patients with HCC.